 | |||||||
| finance | |||||||
| NEWS | |||||||
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 ... NEURO-TTRansform study met all co-primary and secondary endpoints · Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease ...
| |||||||
| See more results | Edit this alert | |||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment